Literature DB >> 17980062

Prognostic factors for late urinary toxicity grade 2-3 after conformal radiation therapy on patients with prostate cancer.

Ricardo A Nakamura1, Carlos R Monti, Lisias N Castilho, Felipe A Trevisan, Alexandre C Valim, Jose A Reinato.   

Abstract

OBJECTIVE: Identify prognostic factors associated to late urinary toxicity in patients with prostate cancer submitted to radical conformal radiotherapy (3DCRT).
MATERIALS AND METHODS: From July 1997 to January 2002, 285 patients with localized prostate cancer were consecutively treated with 3DCRT and retrospectively analyzed. Thirty seven (13%) patients were submitted to transurethral prostate resection previously to 3DCRT. The median dose delivered to the prostate was 7920 cGy (7020-8460). Patient and treatment characteristics were analyzed and correlated to late urinary toxicity grade 2-3, especially whether certain radiation doses applied to certain bladder volumes, when visualized through computerized tomography (CT) planning, correlated with the observed actuarial incidences of late urinary complications, using bladder volume as a continuous variable.
RESULTS: On a median follow-up of 53.6 months (3.6-95.3), the 5-year actuarial free from late urinary toxicity grade 2-3 survival was 91.1%. Seven and fifteen patients presented late urinary toxicity grades 2 and 3, respectively. Prior transurethral resection of prostate and radiation dose over 70 Gy on 30% of initial bladder volume were independent prognostic factors for late urinary toxicity grade 2-3.
CONCLUSIONS: This study suggests that restricting radiation doses to 70 Gy or less on 30% of bladder volume, visualized through CT planning, may reduce late urinary complications. It furthermore suggests that patients with prior transurethral resection of prostate may indicate a group of patients with a greater risk for late urinary toxicity grade 2-3 after 3DCRT.

Entities:  

Mesh:

Year:  2007        PMID: 17980062     DOI: 10.1590/s1677-55382007000500006

Source DB:  PubMed          Journal:  Int Braz J Urol        ISSN: 1677-5538            Impact factor:   1.541


  2 in total

1.  Hypofractionated helical tomotherapy using 2.5-2.6 Gy daily fractions for localized prostate cancer.

Authors:  Jose Luis Lopez Guerra; Nicolas Isa; Raul Matute; Moises Russo; Fernando Puebla; Michelle Miran Kim; Alberto Sanchez-Reyes; Cesar Beltran; Javier Jaen; Celine Bourgier; Hugo Marsiglia
Journal:  Clin Transl Oncol       Date:  2012-07-24       Impact factor: 3.405

2.  Urinary function and quality of life after radiotherapy for prostate cancer in patients with prior history of surgical treatment for benign prostatic hyperplasia.

Authors:  Mélanie Guilhen; Christophe Hennequin; Idir Ouzaid; Ingrid Fumagalli; Valentine Martin; Sophie Guillerm; Pierre Mongiat-Artus; Vincent Ravery; François Desgrandchamps; Laurent Quéro
Journal:  Radiat Oncol       Date:  2018-10-24       Impact factor: 3.481

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.